Seattle biotech startup AltPep raises $23.1M to tackle Alzheimer’s and related diseases
January 14, 2021 at 3:54 pm
Valerie Daggett, founder and CEO of AltPep. (UW Photo)
AltPep, a Seattle-based biotech startup tackling amyloid protein disorders, has raised $23.1 million in a Series A funding round.
The venture spun out the University of Washington in March 2019. Its founder and CEO is Valerie Daggett, a longtime professor in the Department of Bioengineering in the College of Engineering.
AltPep is developing tools and treatments for diseases caused by amyloid proteins that are incorrectly folded and create harmful deposits. These deposits can lead to numerous amyloid diseases including Alzheimer’s, Parkinson’s, type-2 diabetes, some kinds of drug-resistant bacterial infections, and dozens more.
AltPep Raises $23M Jumpstarting Work on Alzheimer s Disease
Search jobs SEATTLE - January 14, 2021 - (Newswire.com)
AltPep Corporation, a privately held biomedical company focused on diagnosing and treating Central Nervous System amyloid disorders, starting with Alzheimer s Disease, today announced it closed a $23.150 million Series A investment round. Matrix Capital Management led the investment, with significant participation by Alexandria Venture Investments. In conjunction with the financing, David Goel, Managing General Partner and Founder of Matrix Capital Management and Joel Marcus, Executive Chairman and Founder of Alexandria Real Estate Equities/Alexandria Venture Investments, have joined the AltPep Board of Directors.
The proceeds of the Series A investment will be used to advance a breakthrough technology developed at the University of Washington laboratory of AltPep Founder and CEO, Valerie Daggett, Ph.D., that targets the misfolded forms of amyloi
Biomanufacturing Site Coming To Alexandria s Watertown Campus The future site of a 40K SF biomanufacturing facility at Alexandria s The Arsenal on the Charles.
The region’s biggest life sciences players have teamed up to deliver a much-needed biomanufacturing facility just miles away from the market’s Kendall Square epicenter.
The Massachusetts Center for Advanced Biological Innovation and Manufacturing, called CABIM, has signed a 40K SF lease at The Arsenal on the Charles in Watertown with Alexandria Real Estate Equities, it announced Thursday. The upcoming biomanufacturing center is backed by $76M in financing in a round led by Harvard University, as well as the Massachusetts Institute of Technology, life sciences companies and area hospitals.
Alexandria Real Estate Equities (ARE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
Author Bio
Matt is a Certified Financial Planner based in South Carolina who has been writing for The Motley Fool since 2012. Matt specializes in writing about bank stocks, REITs, and personal finance, but he loves any investment at the right price. Follow him on Twitter to keep up with his latest work!
Follow @TMFMathGuy
The need for life science properties is growing exponentially in the United States and not just for developing COVID-19 vaccines and treatments. Innovation in the healthcare industry has never been more active, and the need for state-of-the art properties to conduct research and development is increasing.